These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16108417)

  • 21. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
    Stull DE; Vernon MK; Legg JC; Viswanathan HN; Fairclough D; Revicki DA
    Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic use of erythropoietin in dermatooncology.
    Satzger I; Schenck F; Thol F; Ganser A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2007 Apr; 5(4):280-5. PubMed ID: 17376091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J
    Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J; Wauters I
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing chemotherapy-induced anemia management with the use of patient flow sheets.
    Morehead L; Zobec A; Pacheco-Gach C; Glick R; Flippin SB
    J Support Oncol; 2005; 3(6 Suppl 4):14-5. PubMed ID: 16355551
    [No Abstract]   [Full Text] [Related]  

  • 29. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
    Borget I; Chouaid C; Demarteau N; Annemans L; Pujol JL
    Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S; Mirtsching B; Charu V; Terry D; Rossi G; Tomita D; McGuire WP
    J Support Oncol; 2003; 1(2):131-8. PubMed ID: 15352656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
    Pedrazzoli P; Farris A; Del Prete S; Del Gaizo F; Ferrari D; Bianchessi C; Colucci G; Desogus A; Gamucci T; Pappalardo A; Fornarini G; Pozzi P; Fabi A; Labianca R; Di Costanzo F; Secondino S; Crucitta E; Apolloni F; Del Santo A; Siena S
    J Clin Oncol; 2008 Apr; 26(10):1619-25. PubMed ID: 18375891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
    Koopman W; Iakiri S
    J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.